Agenus reported third-quarter 2026 results alongside progress on its lead cancer-drug combination, botensilimab and balstilimab, known as BOT+BAL. The company is preparing a global Phase 3 trial in high-risk, early-stage microsatellite-stable (MSS) colon cancer and said the first marketing authorizations for the combination have been granted in Armenia.
Agenus also highlighted positive operating income for a third consecutive quarter and $86.9 million in cash, cash equivalents and short-term investments at quarter-end. It said a recent financing is intended to support the trial and company operations through 2031.
Clinical development and trial plans
- The Phase 3 ROBBIN trial is designed to test BOT+BAL before surgery in about 850 patients with high-risk Stage II or Stage III MSS colon cancer. Its primary endpoint is event-free survival.
- Agenus expects to enroll the first patient in the first quarter of 2027. Site preparation is progressing across the Americas, Europe and Asia.
- The company anticipates an interim assessment of pathologic response in the first 100 patients enrolled in the fourth quarter of 2027.
- Two peer-reviewed Phase 2 studies underpin the trial. In NEST, about 32% of patients with MSS tumors had a pathologic complete response; in the MSS group in UNICORN, the rate was 29%, with a 36% major pathologic response rate.
- Neither study reported a recurrence in its BOT+BAL cohort at the reported data cutoffs. Median follow-up ranged from 23.5 to 32.2 months in the NEST cohorts and was 19.2 months in UNICORN. These are Phase 2 findings, not results from the ongoing Phase 3 trial.
- Surgery proceeded as planned for most participants: Agenus said BOT+BAL did not delay planned surgery in NEST and 98% of UNICORN participants underwent surgery on schedule. No new safety concerns were identified in those studies.
- The company also cited results from a separate study in mismatch repair-deficient colon cancer, a distinct population from ROBBIN’s target group. In that study, 72% of 18 patients had a pathologic complete response after six weeks of BOT+BAL.
Other clinical evidence and commercial progress
- Agenus cited longer-term results from its C-800-01 program in advanced cancers. Among heavily pretreated patients with MSS metastatic colorectal cancer without active liver metastases, three-year overall survival was 33%. In a heavily pretreated recurrent ovarian cancer cohort, estimated three-year overall survival was 48%. These findings come from advanced-disease studies, not the early-stage ROBBIN population.
- The company said year-to-date pre-commercial product revenue from global patient access programs was $17.0 million.
- The first marketing authorizations for BOT+BAL were granted in Armenia. The announcement did not provide further detail on the scope of those authorizations or expected sales.
Financial position and financing
- Agenus said it had $86.9 million in cash, cash equivalents and short-term investments at September 30, and positive operating income for the third straight quarter. The results announcement excerpt did not give specific quarterly revenue, net income or cash-flow figures.
- A July private placement generated about $85 million in upfront gross proceeds. It also included milestone-linked warrants that could provide additional proceeds; the available announcement text does not specify the potential amount.
- Agenus said the financing supports ROBBIN’s development and corporate operations through 2031.
What changes for investors
The immediate change is that BOT+BAL has received its first marketing authorizations, while its largest stated development step remains ahead: starting the global Phase 3 ROBBIN trial in early 2027. The Phase 2 response and follow-up results provide clinical context for that trial, but they do not establish whether BOT+BAL improves outcomes in the broader population ROBBIN is designed to study. The financing extends the company’s stated operating runway, while the milestone-linked warrants represent a potential additional source of capital.